Website: https://www.kangh.com
Chengdu Kanghua Biological Products Co., Ltd. (KANGHUA), located in the Economic & Technological Development Zone in Longquanyi District of Chengdu, Sichuan Province, is established in 2004, it mainly engaged in R&D, production and distribution of human vaccines, cytokines and rapid test kits. A modern base covering an area of nearly 30,000m2 is used for R&D and production. The advanced hardware facilities, including bio-technology center, SPF laboratory, workshops for production of bacterial and viral vaccine, are all grant to GMP requirements.
KANGHUA also has a stable technology platform for purification and fermentation of bacteria, cultivation of viruses, analysis of animal models, microcarrier culture technology, etc., as well as the production and quality control systems, which meet GMP standards. The product structure of KANGHUA are being completed with new products continuously, including bacterial vaccine, viral vaccines, engineered vaccine, and other bio-pharmaceutical products.
KANGHUA, as the Post-Doctoral Research Center, Sichuan Province Innovative Enterprise, Sichuan Province Creditable Enterprise, has 180 employees in total. The number of employees with Master’s degree in R&D, QA and QC department account for 30%, laying the foundation for rapid growth and increased competitiveness. Our company established a post-doctorate research center in 2008, and built a long-term cooperation relationship with several first-class international scientific research institutes to boost the research and development activity of biological products of KANGHUA.
Under the guidance of the quality principal, KANGHUA established a set of standard and complete quality control systems, which effectively tracking, detecting, and estimating the manufacturing processes to meet GMP requirement completely.
So far, KANGHUA has gained remarkable research results, as several research projects are funded by the government. During those, 15 projects have obtained patents for invention and utility. "Group ACYW135 Meningococcal Polysaccharide Vaccine" is the first product of KANGHUA. "Human Diploid Cell Rabies Vaccine", recognized as "WHO Gold Standard", has been marketed in 2014 with the "New Drug Certificate (GYZZ No. S20120001)" and "Production License" by CFDA. This vaccine is the first Human Diploid Cell Rabies Vaccine in China, which can greatly contribute to the prevention of rabies in China and Asia. In addition, "H5N1 Influenza Vaccine" and "Seasonal Influenza Vaccine" without antiseptic, which have finished the clinical trials, are now on the process of large scale production. Besides, KANGHUA has 6 researching projects, including "Therapeutic Human Papillomavirus Vaccine", "Recombinant Rotavirus Vaccine", "Meningococcal Polysaccharide-DT protein Combined Vaccine", "Encephalitis Vaccine", etc. Some have completed the laboratory research and small-scale production, whose key techniques index has been received qualification evaluation report by "National Institutes for Food and Drug Control".
Currently, KANGHUA's sales network has expanded from China mainland to Southeast Asia, Middle East, Africa, etc. We are trying our best to bring health to all over the world.
Chengdu Kanghua Biological Products Co., Ltd. (KANGHUA), located in the Economic & Technological Development Zone in Longquanyi District of Chengdu, Sichuan Province, is established in 2004, it mainly engaged in R&D, production and distribution of human vaccines, cytokines and rapid test kits. A modern base covering an area of nearly 30,000m2 is used for R&D and production. The advanced hardware facilities, including bio-technology center, SPF laboratory, workshops for production of bacterial and viral vaccine, are all grant to GMP requirements.
KANGHUA also has a stable technology platform for purification and fermentation of bacteria, cultivation of viruses, analysis of animal models, microcarrier culture technology, etc., as well as the production and quality control systems, which meet GMP standards. The product structure of KANGHUA are being completed with new products continuously, including bacterial vaccine, viral vaccines, engineered vaccine, and other bio-pharmaceutical products.
KANGHUA, as the Post-Doctoral Research Center, Sichuan Province Innovative Enterprise, Sichuan Province Creditable Enterprise, has 180 employees in total. The number of employees with Master’s degree in R&D, QA and QC department account for 30%, laying the foundation for rapid growth and increased competitiveness. Our company established a post-doctorate research center in 2008, and built a long-term cooperation relationship with several first-class international scientific research institutes to boost the research and development activity of biological products of KANGHUA.
Under the guidance of the quality principal, KANGHUA established a set of standard and complete quality control systems, which effectively tracking, detecting, and estimating the manufacturing processes to meet GMP requirement completely.
So far, KANGHUA has gained remarkable research results, as several research projects are funded by the government. During those, 15 projects have obtained patents for invention and utility. "Group ACYW135 Meningococcal Polysaccharide Vaccine" is the first product of KANGHUA. "Human Diploid Cell Rabies Vaccine", recognized as "WHO Gold Standard", has been marketed in 2014 with the "New Drug Certificate (GYZZ No. S20120001)" and "Production License" by CFDA. This vaccine is the first Human Diploid Cell Rabies Vaccine in China, which can greatly contribute to the prevention of rabies in China and Asia. In addition, "H5N1 Influenza Vaccine" and "Seasonal Influenza Vaccine" without antiseptic, which have finished the clinical trials, are now on the process of large scale production. Besides, KANGHUA has 6 researching projects, including "Therapeutic Human Papillomavirus Vaccine", "Recombinant Rotavirus Vaccine", "Meningococcal Polysaccharide-DT protein Combined Vaccine", "Encephalitis Vaccine", etc. Some have completed the laboratory research and small-scale production, whose key techniques index has been received qualification evaluation report by "National Institutes for Food and Drug Control".
Currently, KANGHUA's sales network has expanded from China mainland to Southeast Asia, Middle East, Africa, etc. We are trying our best to bring health to all over the world.
Signup today to claim your Discount. Get Started before it's too late!
